Skip to content

Cannabis: all studies

Page 56 of 289: studies 551 to 560 of 2,882, newest first. Back to the cannabis overview

Research

Relationship Between Cannabis Use and Immediate, Delayed, and Working Memory Performance Among Older Adults

Cannabis 2023 Madison Maynard, Daniel Paulson, Michael Dunn et al.

Cannabis is increasingly accessible and use is increasing rapidly among older adults as laws change and cannabis becomes more frequently prescribed in healthcare settings. Past research identified cognitive effects of cannabis use among adolescents and young adults that can persist for several weeks after intoxication, though little is known about how these effects generalize to older adults....

Medical Cannabis sativa (Marijuana or drug type): Psychoactive molecule, Δ9-Tetrahydrocannabinol (Δ9-THC)

International Journal of Research and Innovation in Applied Science 2023 Ravindra B. Malabadi, Kiran P. Kolkar, Raju K. Chalannavar et al. 4 citations

This review paper highlights about Medical Cannabis sativa (Marijuana or drug type) containing psychoactive molecule, Δ9-Tetrahydrocannabinol (Δ9-THC) as a part of educational awareness programme in India. Cannabis sativa and Cannabis indica were originally a native of India growing as a wild notorious noxious weed in the Indian Himalayan region. Marijuana (Charas, Ganja and Bhang in India) is...

First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness.

Psychiatry Research 2023 Ricci Valerio, Ceci Franca, Di Carlo Francesco et al.

BACKGROUND Natural Cannabis (NC) and Synthetic Cannabinoids (SCs) use can increase the risk of developing psychotic disorders and exacerbate their course. AIMS To examine the differences between psychoses not associated with cannabis use and those associated with NC and SCs use, evaluating psychotic symptoms, global functioning, dissociative symptoms and suicidal ideation. METHODS The sample of...

Psychotropic Effects of Cannabis

Plant-Based Therapeutics, Volume 1 2023 Ivan A. Ross

Brain development is a complex phenomenon from fetal life to adolescence. During this period, the brain’s maturation proceeds through a series of ordered events, including critical periods of plasticity. The brain is particularly sensitive to the environment during the changes. The endocannabinoid system participates directly and indirectly in the plasticity and maturation processes. The main...

A Content Analysis of Social Media Discussions on THC-O-Acetate.

Cannabis 2023 Daniel J. Kruger, Karahmet Amila, Sydney M Kaplan et al. 15 citations

Novel cannabinoids require systematic research to inform policies and practices. There is a growing interest in semi-synthetic cannabinoids by consumers, manufacturers, and regulators. However, there is a scarcity of research on these substances. Online discussion forums can provide guidance for research questions when current knowledge is scarce. The current project investigates the topics and...

DOI: 10.26828/cannabis/2023/000164 (opens in new tab) Full text (opens in new tab) = THC-O-Acetate Reddit Ketene Qualitative analysis +1

Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician's perspective.

Expert Review of Clinical Pharmacology 2023 Luke J. Ney, Wole Akosile, Chris Davey et al. 8 citations

Preclinical and experimental research have provided promising evidence that medicinal cannabis may be efficacious in the treatment of posttraumatic stress disorder (PTSD). However, implementation of medicinal cannabis into routine clinical therapies may not be straightforward. In this review, we describe some of the clinical, practical, and safety challenges that must be addressed for...

DOI: 10.1080/17512433.2023.2276309 (opens in new tab) Full text (opens in new tab) Cannabis Clinical medicine Exposure therapy Posttraumatic stress disorder

Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.

Frontiers in Psychiatry 2023 Angela N Phan, Garth E Terry 6 citations

Cannabis use disorder (CUD) is prevalent in ~2-5% of adults in the United States and is anticipated to increase as restrictions to cannabis decrease and tetrahydrocannabinol (THC) content in cannabis products increase. No FDA-approved medications for CUD are currently available, despite trials of dozens of re-purposed and novel drugs. Psychedelics have garnered interest as a therapeutic class...

Sustratos genéticos de la psicosis asociada al cannabis

Revista Española de Drogodependencias December 30, 2022 Diego Quattrone

Este artículo resumirá los principales sustratos de las psicosis asociadas al cannabis. En primer lugar, se introducirá un marco epistemológico para apoyar la existencia de una “psicosis asociada al cannabis” específica como entidad nosológica distinta de la esquizofrenia idiopática y otros trastornos psicóticos. A continuación, se examinarán las principales características clínicas de las...

Genetic substrates of cannabis-associated psychosis

Revista Española de Drogodependencias December 30, 2022 Diego Quattrone

This paper will summarise the main substrates of cannabis-associated psychoses. First, an epistemological framework will be introduced to support the existence of a specific ‘cannabisassociated psychosis’ as a nosological entity distinct from idiopathic schizophrenia and other psychotic disorders. Then, the main clinical characteristics of cannabis-associated psychoses will be examined....

DOI: 10.54108/10030 (opens in new tab) Cannabidiol Psychosis Schizophrenia object-oriented programming Effects of cannabis +1

Effects of acute Δ9 -tetrahydrocannabinol on behavior and the endocannabinoid system in HIV-1 Tat transgenic female and male mice

Research Square December 29, 2022 Barkha J. Yadav-Samudrala, Ben L. Gorman, Hailey Dodson et al. 1 citation preprint

Abstract Cannabis use is highly prevalent especially among people living with HIV (PLWH). Activation of the anti-inflammatory and neuroprotective endocannabinoid system by phytocannabinoids, i.e. Δ9-tetrahydrocannabinol (THC), has been proposed to reduce HIV symptoms. However, THC’s effects on HIV-associated cognitive impairments are unclear. Using HIV-1 Tat transgenic mice, the current study...